Regeneron (REGN) Posted Solid Quarterly Results, Eyes 2026 Pipeline Catalysts

Core Insights - Chautauqua Capital Management's fourth-quarter 2025 investor letter highlights a strong performance in global equities, with international markets outperforming U.S. equities significantly, aided by a weaker dollar and improving trade conditions [1] - The Baird Chautauqua International Growth Fund returned +0.11% in Q4 2025, lagging behind the MSCI ACWI ex-U.S. Index's +5.05%, while the Global Growth Fund gained +4.18%, outperforming its MSCI ACWI Index® ND's +3.29% [1] - The fund remains focused on high-quality businesses with strong cash flows and balance sheets, despite near-term headwinds from sector rotations and profit-taking in Greater China [1] Company-Specific Insights - Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) is highlighted as a biotechnology leader with a focus on innovative medicines for serious diseases, reporting a one-month return of approximately -0.30% and shares remaining about 12.42% above their 52-week high [2] - As of January 26, 2026, Regeneron's stock closed at approximately $762.65 per share, with a market capitalization of about $81.779 billion [2] - Regeneron reported strong Q3 2025 results, with top- and bottom-line beats driven by Dupixent and Eylea HD, and expects resolution of manufacturing issues in 2026 along with important pipeline data readouts [3] - Regeneron is not among the 30 Most Popular Stocks Among Hedge Funds, with 78 hedge fund portfolios holding the stock at the end of Q3, an increase from 73 in the previous quarter [3]